{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:34:27Z","timestamp":1791434067736,"version":"4.3.3"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ymgme.2023.108113","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:23:14Z","timestamp":1702570994000},"page":"108113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults"],"prefix":"10.1016","volume":"141","author":[{"given":"Cecile","family":"Paquet Luzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Doppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Polasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgme.2023.108113_bb0005","article-title":"Lysosomal storage diseases","volume":"1","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ymgme.2023.108113_bb0010","series-title":"Metabolic Diseases: Foundations of Clinical Management, Genetics, and Pathology","first-page":"367","article-title":"Lysosomal storage diseases","author":"Ferreira","year":"2017"},{"key":"10.1016\/j.ymgme.2023.108113_bb0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/B978-0-444-64029-1.00022-9","article-title":"Inborn errors of metabolism","volume":"162","author":"Ferreira","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1039\/D2MO00004K","article-title":"Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders","volume":"18","author":"Li","year":"2022","journal-title":"Mol. Omics."},{"key":"10.1016\/j.ymgme.2023.108113_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183336","article-title":"Inherited disorders of lysosomal membrane transporters","volume":"1862","author":"Huizing","year":"2020","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ymgme.2023.108113_bb0030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymgme.2023.108113_bb0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.ymgme.2023.108113_bb0040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/clinchem\/13.7.565","article-title":"Enzymatic abnormalities in diseases of sphingolipid metabolism","volume":"13","author":"Brady","year":"1967","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1098\/rstb.2003.1276","article-title":"Neurobiology and cellular pathogenesis of glycolipid storage diseases","volume":"358","author":"Walkley","year":"2003","journal-title":"Philos. Trans. R. Soc. B"},{"key":"10.1016\/j.ymgme.2023.108113_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040601","article-title":"Advances in drug discovery targeting lysosomal membrane proteins","volume":"16","author":"Wang","year":"2023","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.ymgme.2023.108113_bb0060","series-title":"Lysosomal Enzyme Replacement Therapies: Historical Development, Clinical Outcomes, and Future Perspectives","author":"Solomon","year":"2023"},{"key":"10.1016\/j.ymgme.2023.108113_bb0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymgme.2023.108113_bb0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/ETLS20180058","article-title":"Substrate reduction therapy for inborn errors of metabolism","volume":"3","author":"Yue","year":"2019","journal-title":"Emerg. Top. Life Sci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0075","doi-asserted-by":"crossref","first-page":"21758","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2023.108113_bb0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ymgme.2012.01.020","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann\u2013Pick C mice","volume":"105","author":"Nietupski","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108113_bb0085","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.ymgme.2023.108113_bb0090","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.ymgme.2023.108113_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","article-title":"Low-dose N-Butyldeoxynojirimycin (OGT 918) for type I Gaucher disease","volume":"28","author":"Heitner","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2023.108113_bb0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/13543784.12.2.273","article-title":"Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1","volume":"12","author":"Pastores","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2023.108113_bb0105","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2023.108113_bb0110","series-title":"Miglustat for Treatment of Niemann-Pick C Disease: A Randomised Controlled Study","first-page":"765","volume":"6","author":"Patterson","year":"2007"},{"key":"10.1016\/j.ymgme.2023.108113_bb0115","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1021\/jm501181z","article-title":"Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase\/neutral glucosylceramidase inhibitors","volume":"57","author":"Ghisaidoobe","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0120","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ymthe.2022.11.015","article-title":"Targeting the central nervous system in lysosomal storage diseases: strategies to deliver therapeutics across the blood-brain barrier","volume":"31","author":"Critchley","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2023.108113_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114464","article-title":"Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders","volume":"188","author":"Del Grosso","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymgme.2023.108113_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.559804","article-title":"CNS-targeting therapies for lysosomal storage diseases: current advances and challenges","volume":"7","author":"Edelmann","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0135","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.108113_bb0140","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2174\/1381612825666190708213159","article-title":"New advanced strategies for the treatment of lysosomal diseases affecting the central nervous system","volume":"25","author":"Gigliobianco","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgme.2023.108113_bb0145","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2023.108113_bb0150","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.ymgme.2023.108113_bb0155","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.ymgme.2023.108113_bb0160","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2023.108113_bb0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.ymgme.2023.108113_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","article-title":"Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers","volume":"51","author":"Peterschmitt","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.107193","article-title":"AZ-3102 significantly increases survival and decreases neuroinflammation in a mouse model of Sandhoff disease","volume":"138","author":"Landskroner","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108113_bb0180","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/glycob\/cwab046","article-title":"Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease","volume":"31","author":"Reza","year":"2021","journal-title":"Glycobiology."},{"key":"10.1016\/j.ymgme.2023.108113_bb0185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ymgme.2016.11.390","article-title":"The metabolism of glucocerebrosides \u2014 From 1965 to the present","volume":"120","author":"Futerman","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108113_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphingolipid metabolism: from synthesis to breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/genes10070510","article-title":"Insight into the role of extracellular vesicles in lysosomal storage disorders","volume":"10","author":"Tancini","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymgme.2023.108113_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-5793(92)80970-R","article-title":"\u03b2-Glucosidase activity towards a bile acid glucoside in human liver","volume":"314","author":"Matern","year":"1992","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2023.108113_bb0205","doi-asserted-by":"crossref","first-page":"11261","DOI":"10.1074\/jbc.272.17.11261","article-title":"Purification and characterization of a microsomal bile acid \u03b2- glucosidase from human liver","volume":"272","author":"Matern","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0210","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neuropharm.2016.08.011","article-title":"Cholesterol-dependent increases in glucosylceramide synthase activity in Niemann-pick disease type C model cells: abnormal trafficking of endogenously formed ceramide metabolites by inhibition of the enzyme","volume":"110","author":"Hashimoto","year":"2016","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.ymgme.2023.108113_bb0215","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1074\/jbc.M610544200","article-title":"Identification of the non-lysosomal glucosylceramidase as \u03b2-glucosidase 2","volume":"282","author":"Boot","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11064-016-1833-0","article-title":"Erratum to: current and novel aspects on the non-lysosomal \u03b2-Glucosylceramidase GBA2 (neurochemical research, (2016), 10.1007\/s11064-015-1763-2)","volume":"41","author":"Aureli","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymgme.2023.108113_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030736","article-title":"Glucocerebrosidase: functions in and beyond the lysosome","volume":"9","author":"Boer","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2023.108113_bb0230","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1478-3231.2012.02841.x","article-title":"Beta-glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration","volume":"32","author":"Gonzalez-Carmona","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.ymgme.2023.108113_bb0235","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/febs.14744","article-title":"In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling","volume":"286","author":"Kuo","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.ymgme.2023.108113_bb0240","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1194\/jlr.RA119000154","article-title":"Role of \u03b2-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish","volume":"60","author":"Lelieveld","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2023.108113_bb0245","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000327380","article-title":"Knock-out of \u03b2-glucosidase 2 has no influence on dextran sulfate sodium-induced colitis","volume":"84","author":"Scharl","year":"2011","journal-title":"Digestion."},{"key":"10.1016\/j.ymgme.2023.108113_bb0250","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1074\/jbc.M116.762831","article-title":"Identification of a feedback loop involving \u03b2-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease","volume":"292","author":"Schonauer","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0255","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1096\/fj.12-215152","article-title":"The nonlysosomal \u03b2-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells","volume":"27","author":"Sorli","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2023.108113_bb0260","first-page":"177","article-title":"Van Der Spoel, characterization of the zebrafish homolog of \u03b2-glucosidase 2: a target of the drug Miglustat","volume":"13","author":"Sultana","year":"2016"},{"key":"10.1016\/j.ymgme.2023.108113_bb0265","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fnmol.2017.00386","article-title":"The enigmatic role of GBA2 in controlling locomotor function","volume":"10","author":"Woeste","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0270","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1074\/jbc.RA119.012502","article-title":"Glucocerebrosidases catalyze a transgalactosylation reaction that yields a newly-identified brain sterol metabolite, galactosylated cholesterol","volume":"295","author":"Akiyama","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0275","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1074\/jbc.M112.414714","article-title":"The non-lysosomal \u03b2-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi","volume":"288","author":"K\u00f6rschen","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1042\/EBC20190091","article-title":"Role of bioactive sphingolipids in physiology and pathology","volume":"64","author":"Gomez-Larrauri","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147353","article-title":"Novelty of sphingolipids in the central nervous system physiology and disease: focusing on the sphingolipid hypothesis of Neuroinflammation and neurodegeneration","volume":"22","author":"Ayub","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030616","article-title":"Neuropathophysiology of lysosomal storage diseases: synaptic dysfunction as a starting point for disease progression","volume":"9","author":"Par\u00e1","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2023.108113_bb0295","doi-asserted-by":"crossref","first-page":"1137893","DOI":"10.3389\/fnins.2023.1137893","article-title":"Sphingolipids in neurodegenerative diseases","volume":"17","author":"Pan","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0300","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/jnc.14540","article-title":"Sphingolipids and neuronal degeneration in lysosomal storage disorders","volume":"148","author":"Grassi","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0310","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/taap.1996.8029","article-title":"Sphingolipids-the enigmatic lipid class: biochemistry, physiology, and pathophysiology 1","volume":"142","author":"Merrill","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00807","article-title":"Sphingosine 1-phosphate receptors and metabolic enzymes as Druggable targets for brain diseases","volume":"10","author":"Grassi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0320","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1194\/jlr.TR119000427","article-title":"Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases","volume":"61","author":"Grassi","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2023.108113_bb0325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.arr.2016.05.004","article-title":"Disorders of lysosomal acidification - the emerging role of v-ATPase in aging and neurodegenerative disease","volume":"32","author":"Colacurcio","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ymgme.2023.108113_bb0330","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2183\/pjab.95.018","article-title":"Vacuolar-type ATPase: A proton pump to lysosomal trafficking","volume":"95","author":"Futai","year":"2019","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-020-00196-0","article-title":"The emerging roles of vacuolar-type ATPase-dependent lysosomal acidification in neurodegenerative diseases","volume":"9","author":"Song","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ymgme.2023.108113_bb0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbabio.2004.04.013","article-title":"Diverse and essential roles of mammalian vacuolar-type proton pump ATPase: toward the physiological understanding of inside acidic compartments","volume":"1658","author":"Sun-Wada","year":"2004","journal-title":"Biochimica et Biophysica Acta (BBA) Bioenergetics."},{"key":"10.1016\/j.ymgme.2023.108113_bb0345","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nbd.2019.03.005","article-title":"Cytosolic glucosylceramide regulates endolysosomal function in Niemann-pick type C disease","volume":"127","author":"Wheeler","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2023.108113_bb0350","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbrc.2015.07.112","article-title":"Lack of enzyme activity in GBA2 mutants associated with hereditary spastic paraplegia\/cerebellar ataxia (SPG46)","volume":"465","author":"Sultana","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2023.108113_bb0355","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2023.108113_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135889","article-title":"Reducing GBA2 activity ameliorates neuropathology in Niemann-pick type C mice","volume":"10","author":"Marques","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2023.108113_bb0365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymgme.2019.04.007","article-title":"Ganglioside GM2 catabolism is inhibited by storage compounds of mucopolysaccharidoses and by cationic amphiphilic drugs","volume":"128","author":"Anheuser","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108113_bb0370","first-page":"461","article-title":"Lysosomal glycosphingolipid storage diseases","volume":"88","author":"Breiden","year":"2019"},{"key":"10.1016\/j.ymgme.2023.108113_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072566","article-title":"Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease","volume":"21","author":"Breiden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.108113_bb0380","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jbior.2018.08.001","article-title":"Niemann-pick type C disease: the atypical sphingolipidosis","volume":"70","author":"Newton","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.ymgme.2023.108113_bb0385","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-3-031-12390-0_12","article-title":"Neuronal ganglioside and glycosphingolipid (GSL) metabolism and disease\u00a0: cascades of secondary metabolic errors can generate complex pathologies (in LSDs)","volume":"29","author":"Sandhoff","year":"2023","journal-title":"Adv Neurobiol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0390","article-title":"TPC2 rescues lysosomal storage in mucolipidosis type IV, Niemann\u2013Pick type C1, and Batten disease","volume":"14","author":"Rosato","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2023.108113_bb0395","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcdb.2004.03.002","article-title":"Secondary accumulation of gangliosides in lysosomal storage disorders","volume":"15","author":"Walkley","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0400","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbalip.2013.08.010","article-title":"The role of sphingolipid metabolism in cutaneous permeability barrier formation","volume":"1841","author":"Breiden","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA) Mol. Cell Biol. Lipids."},{"key":"10.1016\/j.ymgme.2023.108113_bb0405","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1523-1747.2002.01836.x","article-title":"Human epidermal glucosylceramides are major precursors of stratum corneum ceramides","volume":"119","author":"Hamanaka","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.ymgme.2023.108113_bb0410","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1074\/jbc.M610304200","article-title":"Integrity and barrier function of the epidermis critically depend on glucosylceramide synthesis","volume":"282","author":"Jennemann","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2023.108113_bb0415","series-title":"12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease","author":"Randomized, Double Blind, Placebo Controlled, Multicenter","year":"2023"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:54:49Z","timestamp":1761090889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223007436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1096719223007436"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108113","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108113"}}